Salem, NH, August 07, 2014 --(PR.com
)-- ALPCO is now offering a menu of pancreatic cell antibodies, providing the islet research community with a tool for the identification and isolation of major human pancreatic cell types. These monoclonal antibodies are available in an unconjugated format as well as labeled with FITC, PE or APC for use in either immunohistochemistry or flow cytometry applications.
These pancreatic cell antibodies react with human cell surface molecules on alpha, beta, acinar and duct cells. The panels also include reagents that selectively react with pancreatic adenocarcinomas, but not with abnormal pancreatic cells.
“The ability to selectively isolate functionally diverse pancreatic cell populations has long been a need of researchers studying various aspects of pancreas biology,” explains ALPCO President, Sean Conley. “ALPCO is proud to be able to now provide researchers with a new set of investigating, identifying, and isolating major pancreatic cell populations under our new SPECTRU™ Flow Cytometry brand.”
To learn more about these new pancreatic cell antibodies, visit http://www.alpco.com/products/Pancreatic_Antibodies.aspx
ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care. ALPCO’s product portfolio includes applications for immunoassays, HPLC, LC-MS/MS, purified antibodies, recombinant proteins, flow cytometry reagents, and a new STELLUX™ chemiluminescent assay platform. http://www.alpco.com